Chronic hepatitis C in long term survivors of haematological malignancy treated in a single centre.
OBJECTIVE
To investigate the impact of hepatitis C virus (HCV) infection in long term survivors of haematological malignancy treated before the introduction of blood donor screening in September 1991.


METHODS
Patients were tested for evidence of HCV infection by third generation enzyme linked immunosorbent assays, a recombinant immunoblot assay and reverse transcriptase polymerase chain reaction. Serum aspartate aminotransferase activities were measured. The number and type of blood component units received by each patient were recorded.


RESULTS
Forty two patients were studied who had received a total of 7143 blood component units. Two patients (4.8%) were found to have HCV infection, both had histological evidence of chronic active hepatitis, and one is now receiving treatment with alpha-interferon. Both of these patients had been missed by the ongoing look-back programme which aims to detect recipients of all known HCV infected blood components.


CONCLUSIONS
Although HCV infection affects a minority of long term survivors of haematological malignancy, infected patients may benefit from alpha-interferon treatment. The screening of all patients treated for haematological malignancy before September 1991 is advocated.
Neilson
J R
JR
Department of Haematology, Birmingham Heartlands Hospital.
Harrison
P
P
Skidmore
S J
SJ
King
J A
JA
Collingham
K E
KE
Milligan
D W
DW
D000328:Adult; D000368:Aged; D001803:Blood Transfusion; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006526:Hepatitis C / Q000235:genetics / Q000276:immunology* / Q000635:transmission*; D018937:Hepatitis C Antibodies / Q000097:blood*; D006521:Hepatitis, Chronic / Q000276:immunology*; D006801:Humans; D015151:Immunoblotting; D007938:Leukemia / Q000628:therapy / Q000821:virology*; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D015995:Prevalence; D012367:RNA, Viral / Q000032:analysis; D017741:Survivors; D013997:Time Factors
D018937:Hepatitis C Antibodies; D012367:RNA, Viral